Administrative Core

$51,134P01FY2013AINIH

Beth Israel Deaconess Medical Center, Boston MA

Investigators

Linked publications & trials

Paper 36902453 Paper 31057553 Paper 30482849 Paper 30058241 Paper 28980301 Paper 28751772 Paper 28076903 Paper 27992687 Paper 27695002 Paper 27581174 Paper 27482100 Paper 27368806 Paper 27183584 Paper 27029059 Paper 26794910 Paper 26667173 Paper 26339044 Paper 26314831 Paper 25957267 Paper 25926831 Paper 25801878 Paper 25799045 Paper 25678452 Paper 25456769 Paper 25347469 Paper 24941157 Paper 24795728 Paper 24670806 Paper 23629864 Paper 23225888 Paper 22989874 Paper 22768209 Paper 22613797 Paper 22184727 Paper 22088620 Paper 21983784 Paper 21622868 Paper 21561736 Paper 21422172 Paper 21298027 Paper 21278219 Paper 21231893 Paper 20962259 Paper 20818396 Paper 20706608 Paper 20628063 Paper 20609249 Paper 20458333 Paper 20228799 Paper 20146065 Paper 19784369 Paper 19426211 Paper 19387462 Paper 19217684 Paper 19098911 Paper 18852889 Paper 18852199 Paper 18654571 Paper 18495325 Paper 18445119 Paper 18437207 Paper 18272545 Paper 18216865 Paper 18059267 Paper 17997607 Paper 16080120

Abstract

PROJECT SUMMARY (See instructions): This application seeks support for elucidating the role ofthe SLAMF receptors in the pathogenesis of Systemic Lupus Erythematosus (SLE) with the ultimate goal to develop SLAMF-based therapeutic strategies that can be applied to SLE patients. Because of the outcomes of our studies with cells derived from SLE patients and our exciting findings with genetically altered mice, which develop lupus-related autoimmunity, we now have the systems in place to dissect how cell interaction mechanisms and signaling initiated by the SLAMF receptors contribute to the control of tolerance to autoantigens and to the pathogenesis of human SLE. These insights and tools are the basis for a Program Project application entitled:

View original record on NIH RePORTER →